抗生素断点：重新定义敏感性如何保持疗效并改善患者护理。
Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care.
作者信息
Redell Mark, Tillotson Glenn
出版信息
P T. 2019 Sep;44(9):542-544.
Abstract
Carbapenems are a primary treatment for infections from multidrug-resistant bacterial pathogens. To maintain their efficacy and control the emergence of further resistance, breakpoints that correspond to recommended doses with appropriate PK/PD target attainment are paramount.
摘要
碳青霉烯类药物是治疗多重耐药细菌病原体感染的主要药物。为保持其疗效并控制进一步耐药性的出现，与达到适当药代动力学/药效学目标的推荐剂量相对应的断点至关重要。
相似文献
1
2
Breakpoints for carbapenemase-producing Enterobacteriaceae: is the problem solved?产碳青霉烯酶肠杆菌科细菌的药敏折点：问题解决了吗？
Enferm Infecc Microbiol Clin. 2014 Dec;32 Suppl 4:33-40. doi: 10.1016/S0213-005X(14)70172-7.
3
Results from the Survey of Antibiotic Resistance (SOAR) 2011-13 in Turkey.2011 - 2013年土耳其抗生素耐药性调查（SOAR）结果。
J Antimicrob Chemother. 2016 May;71 Suppl 1(Suppl 1):i71-83. doi: 10.1093/jac/dkw075.
4
Results from the Survey of Antibiotic Resistance (SOAR) 2009-11 in Vietnam.越南2009 - 2011年抗生素耐药性调查（SOAR）结果。
J Antimicrob Chemother. 2016 May;71 Suppl 1(Suppl 1):i93-102. doi: 10.1093/jac/dkw069.
5
Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria.比较抗微生物药药代动力学/药效学折点与 EUCAST 和 CLSI 革兰阳性菌临床折点。
Int J Antimicrob Agents. 2012 Oct;40(4):313-22. doi: 10.1016/j.ijantimicag.2012.06.005. Epub 2012 Aug 22.
6
Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.俄罗斯 2014-16 年抗生素耐药性调查（SOAR）结果。
J Antimicrob Chemother. 2018 Apr 1;73(suppl_5):v14-v21. doi: 10.1093/jac/dky065.
7
Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones.评估新一代氟喹诺酮类药物的微生物敏感性和预测临床疗效的挑战。
J Ocul Pharmacol Ther. 2012 Feb;28(1):3-11. doi: 10.1089/jop.2011.0072. Epub 2011 Oct 14.
8
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
9
Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.伏立康唑和烟曲霉在体外药代动力学/药效学模型中治疗药物监测的药敏断点和靶值。
J Antimicrob Chemother. 2014 Jun;69(6):1611-9. doi: 10.1093/jac/dku023. Epub 2014 Feb 17.
10
Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.在重症患者中应用药代动力学/药效学原理：优化疗效并减少耐药性产生。
Semin Respir Crit Care Med. 2015 Feb;36(1):136-53. doi: 10.1055/s-0034-1398490. Epub 2015 Feb 2.
引用本文的文献
1
The Practical Problem With Carbapenem Testing and Reporting Accurate Bacterial Susceptibilities.碳青霉烯类检测及报告准确细菌药敏性的实际问题。
Front Pharmacol. 2022 Apr 25;13:841896. doi: 10.3389/fphar.2022.841896. eCollection 2022.
本文引用的文献
1
Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.别紧张：肠杆菌科和铜绿假单胞菌氟喹诺酮类药物的修订折点。
J Clin Microbiol. 2019 Jun 25;57(7). doi: 10.1128/JCM.02072-18. Print 2019 Jul.
2
Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.理解和应对 CLSI 折点修订：临床实验室的入门指南。
J Clin Microbiol. 2019 May 24;57(6). doi: 10.1128/JCM.00203-19. Print 2019 Jun.
3
A Guide to Bacterial Culture Identification And Results Interpretation.细菌培养鉴定与结果解读指南
P T. 2019 Apr;44(4):192-200.
4
Public Health Efforts Can Impact Adoption of Current Susceptibility Breakpoints, but Closer Attention from Regulatory Bodies Is Needed.公共卫生措施可以影响现行药敏折点的采用，但需要监管机构给予更多关注。
J Clin Microbiol. 2019 Feb 27;57(3). doi: 10.1128/JCM.01488-18. Print 2019 Mar.
5
Evaluation of Ciprofloxacin and Levofloxacin Disk Diffusion and Etest Using the 2019 CLSI Breakpoints.采用 2019 年 CLSI 折点评估环丙沙星和左氧氟沙星药敏纸片扩散法和 Etest 法
J Clin Microbiol. 2019 Feb 27;57(3). doi: 10.1128/JCM.01797-18. Print 2019 Mar.
6
Carbapenem-Resistant Enterobacteriaceae Detection Practices in California: What Are We Missing?加州耐碳青霉烯肠杆菌科检测实践：我们遗漏了什么？
Clin Infect Dis. 2018 Mar 19;66(7):1061-1067. doi: 10.1093/cid/cix942.
7
Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.美罗培南-法硼巴坦对产 KPC 阳性肠杆菌科临床分离株的活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01904-17. Print 2018 Jan.
8
Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.美罗培南-法硼巴坦对 2014 年期间全球收集的当代革兰氏阴性分离株进行了测试，包括耐碳青霉烯类、产 KPC、多药耐药和广泛耐药的肠杆菌科。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00567-17. Print 2017 Sep.
9
Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.肠杆菌科细菌引起的尿路感染、肺炎和败血症住院患者的碳青霉烯类耐药性、不适当的经验性治疗及预后
BMC Infect Dis. 2017 Apr 17;17(1):279. doi: 10.1186/s12879-017-2383-z.
10
Impact of Delays between Clinical and Laboratory Standards Institute and Food and Drug Administration Revisions of Interpretive Criteria for Carbapenem-Resistant Enterobacteriaceae.临床和实验室标准协会与美国食品药品监督管理局对耐碳青霉烯类肠杆菌科细菌解释标准修订之间的延迟影响。
J Clin Microbiol. 2016 Nov;54(11):2757-2762. doi: 10.1128/JCM.00635-16. Epub 2016 Aug 31.
Zotero 插件